NASDAQ · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · LARGE CAP
Revolution Medicines, Inc. RVMD
8 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
EPS · FY25
$-5.95
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-58.1%
Net margin · FY25
—
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
—
Revenue, FY2025 · full 8-year series below
Revenue
Net income
Per share
USD -5.95
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-58.1%
Return on equity, FY2025
ROE
Operating margin—
Net margin—
Return on assets-46.1%
Each USD of equity lost 58 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
—
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.20B
Shares outstanding, FY2025
Change, 5 years—
Change, 10 years—
A share split breaks the comparison across the period, so we leave it out.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 2.4B
total assets, end of FY2025
Total assetsUSD 2.4B
EquityUSD 1.6B
CashUSD 383.7M
Current ratio7.14×
Equity funds 69% of total assets.
History
8 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
Revenue $B
0.0
0.0
0.0
0.0
0.0
0.0
0.1
0.0
Operating income $B
−1.2
−0.7
−0.5
−0.3
−0.2
−0.1
−0.1
−0.0
EBITDA $B
−1.2
−0.7
−0.5
−0.3
−0.2
−0.1
−0.1
−0.0
Income tax $B
0.0
−0.0
−0.0
−0.0
0.0
−0.0
−0.0
·
Net income $B
−1.1
−0.6
−0.4
−0.2
−0.2
−0.1
−0.0
−0.0
EPS, diluted $
−5.95
−3.58
−3.86
−3.08
−2.57
−2.01
−22.33
−21.24
Dividend / sh $
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
−0
·
·
ROE %
−58.1
−29.3
−34.8
−38.6
−34.7
−67.2
·
·
Shares out B
0.20
0.19
0.16
0.09
0.07
0.07
0.00
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
22 of 22
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed